New Study Suggests Immune System and Inflammation Play Essential Roles in Hypertension and End-Organ Damage

Share Article

A newly published report states that animals lacking certain immune cells were found to be fully protected from hypertension and, in human studies, immuno-suppressive agents have shown to reduce blood pressure and prevent end-organ damage, such as kidney damage. Agreeing with this report, Nutri-Med Logic Corp adds, since suppression of immune system could only achieved through application of an anti-inflammatory, benefits of an anti-inflammatory diet, such as Omega-3, in hypertensive individuals is indisputable.

A newly published report states that immune system plays an essential role in hypertension and, in animal studies, genetic deletion of genes associated with certain immune cells either fully protected against hypertension or markedly reduced it.

Immune system comprises of two separate systems that work together, those being innate and acquired, with innate immunity remaining unchanged from beginning to the end of life but acquired immunity evolving through learning.

While both of these systems work hand-in-hand to protect the human body but, at times, they also work hand-in-hand in destroying the body. The common element that separates their constructive work from their destructive work is the status of inflammation.

Regulated inflammation is constructive and dysregulated inflammation is destructive. Inflammation (inflammatory stimuli) is a signal that wakes up the immune cells and anti-inflammatory (immune suppressors) reduces the activities of same.

The report states that mice lacking lymphocytes (the cells of acquired immunity) were protected against hypertension and mice lacking macrophages (the main component of innate immunity) had blunted hypertension in response to kidney’s attempt (angiotensin II) to raise blood pressure and that genetic deletion of macrophages markedly reduced hypertension.

The report, also, states hypertensive stimuli initiate signals from the brain to promote inflammation via activation of immune cells (macrophages and T-lymphocytes) and sending them to the kidney and blood vessels, producing inflammatory agents (IL-6 and IL-17), thus causing kidney and blood vessel dysfunction with the end result being blood pressure elevation.

In 2005, Dr. Charles Serhan at Harvard Medical School discovered certain molecules called Resolvin E-1 inhibited the migration of inflammatory cells, which includes macrophages and T-lymphocytes.

Resolvin E-1 is a derivatives of Omega-3 Fatty Acids and many studies, following Dr. Serhan’s discovery, have shown that Resolvin E-1 also promotes the production of the anti-inflammatory agent IL-10 and that Omega-3 confers inhibitory effects on the production of pro-inflammatory mediators and molecules, such as IL-6 and IL-17; both of which are implicated by this report as the causative factor in hypertension and end-organ damage. (1,2,3)

In conclusion, Nutri-Med Logic Corp, agreeing with this report, adds that Omega-3 is the most effective anti-inflammatory nutrient and when taking into account the role of inflammatory immune cells and their production of inflammatory agents in hypertension and end-organ damage, inclusion of anti-inflammatory diet is of paramount importance.

Nutri-Med Logic Corp is the producer of the Natural, Balanced, Deodorized and Concentrated Omega-3, which is also and Pharmaceutical Grade Omega-3

Nutri-Med Logic Corp is also a producer of dietary supplements such as a Pharmaceutical Grade R-Alpha Lipoic Acid (the natural type of Lipoic Acid), a universal anti-oxidant and the dietary supplement of choice for the Diabetics, in Germany for decades;

Producer of PolyEnylPhosphatidylCholine (PPC 425mg), an extract of soy, a pure and effective dietary source of choline and the recommended dietary supplement for those with Fatty Liver and Alcoholic Liver Disease, in Europe for decades.

Nutri-Med Logic's products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and packaged in pharmaceutical facilities.

It must be noted that the studies, statements or sources above and below have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of the dietary supplements, stated herein, nor equate their supplementation to prevention, treatment or cure.

1- Nutr Clin Pract. 2012 Feb;27(1):91-8.
2. Chin Med J (Engl). 2012 Jan;125(2):178-81
3. J Immunol. 2011 Feb 1;186(3):1735-46.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

H.R. Zadeh
Visit website